Titre : Vitamin K epoxide reductases

Vitamin K epoxide reductases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Limit of Detection
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vitamin K epoxide reductases : Questions médicales les plus fréquentes", "headline": "Vitamin K epoxide reductases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vitamin K epoxide reductases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-10", "dateModified": "2025-05-05", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vitamin K epoxide reductases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Mixed function oxygenases", "url": "https://questionsmedicales.fr/mesh/D006899", "about": { "@type": "MedicalCondition", "name": "Mixed function oxygenases", "code": { "@type": "MedicalCode", "code": "D006899", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.682.690.708" } } }, "about": { "@type": "MedicalCondition", "name": "Vitamin K epoxide reductases", "alternateName": "Vitamin K Epoxide Reductases", "code": { "@type": "MedicalCode", "code": "D064417", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Virginie Lattard", "url": "https://questionsmedicales.fr/author/Virginie%20Lattard", "affiliation": { "@type": "Organization", "name": "USC 1233 RS2GP, INRA, VetAgro Sup, Univ Lyon, F-69280 Marcy l'Etoile, France." } }, { "@type": "Person", "name": "Maria Fusaro", "url": "https://questionsmedicales.fr/author/Maria%20Fusaro", "affiliation": { "@type": "Organization", "name": "National Research Council (CNR), Institute of Clinical Physiology (IFC), 56124 Pisa, Italy." } }, { "@type": "Person", "name": "Nolan Chatron", "url": "https://questionsmedicales.fr/author/Nolan%20Chatron", "affiliation": { "@type": "Organization", "name": "USC 1233 RS2GP, INRA, VetAgro Sup, Univ Lyon, F-69280 Marcy l'Etoile, France." } }, { "@type": "Person", "name": "Luba Tchertanov", "url": "https://questionsmedicales.fr/author/Luba%20Tchertanov", "affiliation": { "@type": "Organization", "name": "Centre Borelli, ENS Paris-Saclay, CNRS, Université Paris-Saclay, 4 Avenue Des Sciences, F-91190 Gif-sur-Yvette, France." } }, { "@type": "Person", "name": "Weikai Li", "url": "https://questionsmedicales.fr/author/Weikai%20Li", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: weikai@wustl.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Successful management of delayed presentation of massive paracetamol overdose in a resource-limited setting: A case report from Nepal.", "datePublished": "2022-12-12", "url": "https://questionsmedicales.fr/article/36523377", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ccr3.6733" } }, { "@type": "ScholarlyArticle", "name": "The isolated symptom of unilateral tonsillar enlargement has limited value in adults with a suspected head and neck cancer pathway.", "datePublished": "2022-12-12", "url": "https://questionsmedicales.fr/article/36503634", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1017/S0022215122002535" } }, { "@type": "ScholarlyArticle", "name": "Mechanical mechanism to induce inspiratory flow limitation in obstructive sleep apnea patients revealed from in-vitro studies.", "datePublished": "2022-12-07", "url": "https://questionsmedicales.fr/article/36521227", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jbiomech.2022.111409" } }, { "@type": "ScholarlyArticle", "name": "Phosphorus limitation of early growth differs between nitrogen-fixing and nonfixing dry tropical forest tree species.", "datePublished": "2022-12-02", "url": "https://questionsmedicales.fr/article/36352518", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/nph.18612" } }, { "@type": "ScholarlyArticle", "name": "Facilitators and barriers to health enhancing physical activity in individuals with severe functional limitations after stroke: A qualitative study.", "datePublished": "2022-10-19", "url": "https://questionsmedicales.fr/article/36337530", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpsyg.2022.982302" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Oxidoreductases", "item": "https://questionsmedicales.fr/mesh/D010088" }, { "@type": "ListItem", "position": 5, "name": "Oxygénases", "item": "https://questionsmedicales.fr/mesh/D010105" }, { "@type": "ListItem", "position": 6, "name": "Mixed function oxygenases", "item": "https://questionsmedicales.fr/mesh/D006899" }, { "@type": "ListItem", "position": 7, "name": "Vitamin K epoxide reductases", "item": "https://questionsmedicales.fr/mesh/D064417" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vitamin K epoxide reductases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vitamin K epoxide reductases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vitamin K epoxide reductases", "description": "Comment diagnostiquer une carence en vitamine K ?\nQuels tests sont utilisés pour évaluer l'activité des réductases ?\nQuels symptômes indiquent un dysfonctionnement des réductases ?\nComment les médicaments affectent-ils le diagnostic ?\nQuel rôle joue l'alimentation dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D064417?mesh_terms=Limit+of+Detection&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vitamin K epoxide reductases", "description": "Quels sont les symptômes d'une carence en vitamine K ?\nComment se manifestent les troubles de coagulation ?\nLes douleurs articulaires sont-elles liées aux réductases ?\nQuels signes cutanés peuvent apparaître ?\nLes saignements menstruels peuvent-ils être affectés ?", "url": "https://questionsmedicales.fr/mesh/D064417?mesh_terms=Limit+of+Detection&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vitamin K epoxide reductases", "description": "Comment prévenir une carence en vitamine K ?\nLes suppléments sont-ils recommandés ?\nQuels aliments sont riches en vitamine K ?\nLes personnes âgées ont-elles besoin de plus de vitamine K ?\nComment éviter les interactions médicamenteuses ?", "url": "https://questionsmedicales.fr/mesh/D064417?mesh_terms=Limit+of+Detection&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vitamin K epoxide reductases", "description": "Comment traiter une carence en vitamine K ?\nQuels médicaments peuvent interférer avec les réductases ?\nY a-t-il des traitements alternatifs ?\nComment surveiller l'efficacité du traitement ?\nLes transfusions sanguines sont-elles nécessaires ?", "url": "https://questionsmedicales.fr/mesh/D064417?mesh_terms=Limit+of+Detection&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vitamin K epoxide reductases", "description": "Quelles complications peuvent survenir en cas de carence ?\nLes complications sont-elles réversibles ?\nQuels risques sont associés à un surdosage de vitamine K ?\nLes complications affectent-elles la grossesse ?\nComment les maladies hépatiques influencent-elles les complications ?", "url": "https://questionsmedicales.fr/mesh/D064417?mesh_terms=Limit+of+Detection&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vitamin K epoxide reductases", "description": "Quels sont les facteurs de risque de carence en vitamine K ?\nLes nouveau-nés sont-ils à risque ?\nLes personnes sous anticoagulants sont-elles à risque ?\nLes maladies intestinales augmentent-elles le risque ?\nLes personnes âgées sont-elles plus vulnérables ?", "url": "https://questionsmedicales.fr/mesh/D064417?mesh_terms=Limit+of+Detection&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une carence en vitamine K ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un dosage des niveaux de prothrombine et de vitamine K dans le sang peut indiquer une carence." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des réductases ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de coagulation comme le temps de prothrombine (TP) sont utilisés pour évaluer l'activité." } }, { "@type": "Question", "name": "Quels symptômes indiquent un dysfonctionnement des réductases ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des saignements excessifs ou des ecchymoses fréquentes peuvent indiquer un dysfonctionnement." } }, { "@type": "Question", "name": "Comment les médicaments affectent-ils le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Certains anticoagulants, comme la warfarine, peuvent fausser les résultats des tests de coagulation." } }, { "@type": "Question", "name": "Quel rôle joue l'alimentation dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation pauvre en vitamine K peut contribuer à des résultats anormaux lors des tests." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une carence en vitamine K ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des saignements, des ecchymoses, et des saignements des gencives." } }, { "@type": "Question", "name": "Comment se manifestent les troubles de coagulation ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Ils se manifestent par des saignements prolongés après une blessure ou des hémorragies internes." } }, { "@type": "Question", "name": "Les douleurs articulaires sont-elles liées aux réductases ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs articulaires peuvent survenir en raison de saignements internes dans les articulations." } }, { "@type": "Question", "name": "Quels signes cutanés peuvent apparaître ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des ecchymoses et des éruptions cutanées peuvent apparaître en cas de carence en vitamine K." } }, { "@type": "Question", "name": "Les saignements menstruels peuvent-ils être affectés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des saignements menstruels plus abondants peuvent être un signe de carence en vitamine K." } }, { "@type": "Question", "name": "Comment prévenir une carence en vitamine K ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée riche en légumes à feuilles vertes aide à prévenir la carence." } }, { "@type": "Question", "name": "Les suppléments sont-ils recommandés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des suppléments peuvent être recommandés pour les personnes à risque, comme les nouveau-nés." } }, { "@type": "Question", "name": "Quels aliments sont riches en vitamine K ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les légumes à feuilles vertes, le brocoli et les huiles végétales sont riches en vitamine K." } }, { "@type": "Question", "name": "Les personnes âgées ont-elles besoin de plus de vitamine K ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent nécessiter un apport accru en raison de l'absorption réduite." } }, { "@type": "Question", "name": "Comment éviter les interactions médicamenteuses ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Il est important de consulter un médecin avant de prendre des suppléments ou des médicaments." } }, { "@type": "Question", "name": "Comment traiter une carence en vitamine K ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut des suppléments de vitamine K par voie orale ou intraveineuse." } }, { "@type": "Question", "name": "Quels médicaments peuvent interférer avec les réductases ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les anticoagulants comme la warfarine peuvent inhiber l'activité des réductases." } }, { "@type": "Question", "name": "Y a-t-il des traitements alternatifs ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des modifications alimentaires pour augmenter l'apport en vitamine K peuvent être bénéfiques." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité du traitement ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de coagulation réguliers permettent de surveiller l'efficacité du traitement." } }, { "@type": "Question", "name": "Les transfusions sanguines sont-elles nécessaires ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Dans les cas graves, des transfusions de plasma peuvent être nécessaires pour traiter les saignements." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir en cas de carence ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des hémorragies graves et des troubles de la coagulation." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, avec un traitement approprié, la plupart des complications peuvent être réversibles." } }, { "@type": "Question", "name": "Quels risques sont associés à un surdosage de vitamine K ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Un surdosage peut entraîner des problèmes de coagulation et des réactions allergiques." } }, { "@type": "Question", "name": "Les complications affectent-elles la grossesse ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une carence en vitamine K peut augmenter le risque de complications pendant la grossesse." } }, { "@type": "Question", "name": "Comment les maladies hépatiques influencent-elles les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les maladies hépatiques peuvent altérer le métabolisme de la vitamine K, augmentant les risques de complications." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de carence en vitamine K ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent une alimentation déséquilibrée, des troubles d'absorption et certains médicaments." } }, { "@type": "Question", "name": "Les nouveau-nés sont-ils à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les nouveau-nés ont un risque accru de carence en raison de réserves limitées de vitamine K." } }, { "@type": "Question", "name": "Les personnes sous anticoagulants sont-elles à risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes sous anticoagulants comme la warfarine doivent surveiller leur apport en vitamine K." } }, { "@type": "Question", "name": "Les maladies intestinales augmentent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies comme la maladie cœliaque peuvent affecter l'absorption de la vitamine K." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus vulnérables ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'absorption de la vitamine K peut diminuer avec l'âge, augmentant le risque de carence." } } ] } ] }

Sources (10000 au total)

The isolated symptom of unilateral tonsillar enlargement has limited value in adults with a suspected head and neck cancer pathway.

Given the uncertainty regarding the predictive value of unilateral tonsillar enlargement and/or lesion in malignancies, this study aimed to evaluate the efficacy of unilateral tonsillar enlargement an... All two-week wait referrals received in 2018-2019 were reviewed. All patients referred with unilateral tonsillar enlargement and/or lesion were included and analysed for patient demographic data, pres... A total of 4934 urgent head and neck cancer referrals were analysed, and 1.9 per cent of these had unilateral tonsillar enlargement and/or lesion. Only 10 patients were diagnosed with tonsil cancer. A... The referral criterion for unilateral tonsillar enlargement and/or lesion may be of limited benefit in an already economically challenged National Health Service. Further multicentre studies should be...

Facilitators and barriers to health enhancing physical activity in individuals with severe functional limitations after stroke: A qualitative study.

Patients with chronic conditions are less physically active than the general population despite knowledge of positive effects on physical and mental health. There is a variety of reasons preventing pe... Using a qualitative approach to explore individuals' subjective perspectives in depth, five community-dwelling adults (age 52-72, 2 female, 3 male) living with chronic mobility impairments after strok... The six main categories of facilitators and barriers along the capability, opportunity, motivation-behavior (COM-B) framework were: (1) physical capabilities, (2) psychological capabilities, (3) motiv... While confirming known barriers and facilitators that impact the ability of individuals with functional limitations to be active, the findings highlight the need and opportunities for comprehensive se...

Pulmonary and physical function limitations in aging men with and without HIV from the Multicenter AIDS Cohort Study (MACS).

We examined the associations between pulmonary impairments and physical function and whether age, HIV serostatus, or smoking modified these relationships.... Using Multicenter AIDS Cohort Study data, we examined associations between pulmonary function (diffusing capacity for carbon monoxide [DL... Of 1,048 men, 55% were living with HIV, median age was 57(IQR=48,64) and median cumulative pack-years was 1.2(IQR = 0,18.1); 33% and 13% had impaired DL... Pulmonary impairment and decreased physical function were associated. Preserving pulmonary function may help preserve physical function in aging men with and without HIV....

Limited evidence of patient-to-patient transmission of Staphylococcus aureus strains between children with cystic fibrosis, Queensland, Australia.

Here we used whole genome sequencing (WGS) to understand strain diversity and potential for patient-to-patient transmission of Staphylococcus aureus among children with cystic fibrosis (CF) in Queensl... S. aureus isolates (n = 401) collected between January 2018 and April 2019 from 184 patients with CF (n = 318 isolates) and 76 patients without CF (n = 83 isolates) were subjected to WGS and subsequen... WGS revealed that patients with CF were essentially colonised by the same genotypes as those seen in patients without CF. Sequence types (ST) for our patients with CF were predominantly ST5 (20.1%), S... These results show that WGS is a useful tool for surveillance of S. aureus strains in children with CF and that the strains in our CF cohort were largely consistent with those circulating in patients ...

Development of constructs to measure client satisfaction with pharmacy services in resource-limited settings. A multicenter cross-sectional study.

Satisfaction with pharmacy services has many implications, including the degree of interaction with health care providers, the type and quality of service provided, and the extent to which needs and d... A quantitative cross-sectional study was employed to guide this study. Data were entered into Epi Data, exported to SPSS 26.0, and analyzed using exploratory factor analysis to identify the underlying... The mean overall satisfaction with pharmacy service was found to be (21.62±6.74)/30. There were eight dimensions of pharmacy service identified, and poor customer satisfaction was recorded for the pre... The survey uncovered eight underlying aspects of pharmacy services that influence client satisfaction. A significant gap was recorded with premises and supply chain-related components. These dimension...

The clear reporting of study limitations in the reports of orthodontic randomized controlled trials is not routinely undertaken: A systematic search and review.

To ensure accurate interpretation of the generalizability of trial findings, the clear reporting of limitations is imperative. This review aimed to assess whether study limitations are reported in ful... In this review, RCTs published between January 1, 2011 and December 31, 2021 were identified from 5 orthodontic journals with the highest impact factor. Trial characteristics were extracted from the i... Three hundred and eighty-six trials were analyzed. In relation to the criterion, the clear reporting of trial limitations was deficient across several areas. Most RCTs were published in 2021 (12.7%), ... Authors of trials should not view the reporting of limitations as a weakness of their trial but rather as an opportunity to provide further information to allow clinicians to fully interpret the gener...